Guard Therapeutics completed the acquisition of Disruptive Pharma through a reverse takeover in July 2026. Following completion of the transaction, the listed company will change its name to Disruptive Pharma AB (publ). This LinkedIn page is retained for historical information and is no longer actively updated. For current company information, news and updates, please follow Disruptive Pharma: https://www.linkedin.com/company/disruptive-pharma-ab/
| Website | http://guardtherapeutics.com |
| Employees | 9 (6 on RocketReach) |
| Phone | +46 46 286 50 30 |
| Technologies |
JavaScript
,
HTML
,
Nginx
+4 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Kidney Disease Treatment, Kidney Health, Kidney Failure Treatment, Chronic Kidney Disease, Therapeutic Drug Development, Clinical Stage Biopharmaceutical |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences +40 more (view full list) |
Looking for a particular Guard Therapeutics employee's phone or email?
Guard Therapeutics Questions
Tobias Agervald is the CEO of Guard Therapeutics.
6 people are employed at Guard Therapeutics.
Top Guard Therapeutics Employees
-
Göran Forsberg
Board Member at Guard Therapeutics
Kalmar County, Sweden -
Karin Botha
Chief Financial Officer at Guard Therapeutics
Stockholms län, Sweden2 -
Sara Thuresson
Head of Clinical Operations at Guard Therapeutics
Uppsala, Uppsala County, SE2 -
Wim Wilpshaar
Medical Director at Guard Therapeutics
Amsterdam, NH, NL
Related Companies
G2Crowd Trusted
300K+
Plugin Users
